SCHEDULE 13G/A: Paradigm BioCapital Discloses 7.9% Stake in Cogent Biosciences

Paradigm BioCapital Advisors LP, along with its affiliates, has disclosed a beneficial ownership of 7.9% of Cogent Biosciences, Inc.'s common stock as of March 31, 2025.

Summary

• Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. collectively reported beneficial ownership of 8,963,655 shares of Cogent Biosciences, Inc. common stock.
• This aggregate ownership represents 7.9% of Cogent Biosciences' outstanding common stock.
• Paradigm BioCapital International Fund Ltd., a private investment vehicle managed by Paradigm BioCapital Advisors LP, directly beneficially owns 7,919,367 shares, representing 7.0% of the class.
• The beneficial ownership is primarily held through the Fund and one or more separately managed accounts managed by Paradigm BioCapital Advisors LP.
• The filing states that the securities were not acquired or held for the purpose of changing or influencing the control of Cogent Biosciences, Inc., except for activities solely related to a nomination under Rule 14a-11.
• The percentages of beneficial ownership are based on 113,850,090 shares of Common Stock outstanding as of February 21, 2025, as reported by Cogent Biosciences in its Form 10-K filed on February 25, 2025.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance metrics that would indicate a strong positive or negative sentiment. The act of an investment firm taking a significant stake can be viewed as a positive signal, but the document itself is neutral.

Positives

• The disclosure of a significant stake by an investment firm like Paradigm BioCapital may signal confidence in Cogent Biosciences' future prospects to other investors.

Negatives

• The document itself does not contain explicit negative information regarding Cogent Biosciences' operations or financial health.

Risks

• The document does not explicitly mention risks related to Cogent Biosciences, Inc. or its operations. It is solely an ownership disclosure.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant ownership by an institutional investor in a publicly traded biotechnology company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake can influence investor perception and potentially the stock price, signaling confidence or a potential for future engagement.

Next Steps

• The reporting persons may continue to monitor their investment in Cogent Biosciences, Inc.

Key Dates

Keywords

Cogent Biosciences, Paradigm BioCapital, SEC filing, Schedule 13G, beneficial ownership, common stock, investment firm, biotechnology, pharmaceuticals